产品描述: Hepln-13 is a potent and orally active Hepsin inhibitor with an IC50 of 0.33 µM. Hepln-13 can be used for the research of metastatic prostate cancer |
靶点:
IC50: 0.33 μM (Hepsin);c-Met/HGFR |
体外研究:
Hepln-13 (10 µM; 2 hours; 293 cells) inhibits cleavage. |
体内研究:
HepIn-13 displays dose dependent inhibition of Hepsin overexpression-relevant prostate cancer phenotypes and blocks prostate cancer metastasis. |
参考文献:
1. Tang X, et al. Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. Oncotarget. 2014;5(5):1352-1362. |
溶解性:
Soluble in DMSO |
保存条件:
2-8℃ |
配置溶液浓度参考:
|
1mg |
5mg |
10mg |
1 mM |
3.075 ml |
15.375 ml |
30.75 ml |
5 mM |
0.615 ml |
3.075 ml |
6.15 ml |
10 mM |
0.308 ml |
1.538 ml |
3.075 ml |
50 mM |
0.062 ml |
0.308 ml |
0.615 ml |
|
注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |